Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

CRANBURY, N.J., Feb. 9, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the dosing of the first subject in a Phase 2 clinical trial designed to evaluate the co-administration of its investigational drug Amigal™ (migalastat hydrochloride) with enzyme replacement therapy (ERT) for Fabry disease.  This open-label Phase 2 study is investigating drug-drug interactions between Amigal and the ERTs Fabrazyme® and Replagal®.  Preclinical studies have demonstrated that coadministration of Amigal results in a prolonged circulating half-life of ERT, increased enzyme activity in cells, and greater substrate reduction in target tissues compared to that seen with ERT alone.  Amigal is being developed in collaboration with GlaxoSmithKline (GSK), as part of an alliance between GSK Rare Diseases and Amicus.

John F. Crowley, Chairman and CEO of Amicus, stated "The commencement of this clinical study is an important milestone for Amicus and for pharmacological chaperone technology.  Based on encouraging preclinical results we believe the co-administration of Amigal with ERT has the potential to provide significant benefit for people with Fabry disease.  The advancement of this approach is a part of our vision to provide two new treatment options for Fabry patients in the future—Amigal as a monotherapy or Amigal co-administered with ERT.  Finally, we also believe this study will provide us with valuable proof of concept for applying this approach to other lysosomal storage diseases and more broadly to other indications treated with therapeutic proteins."  

Phase 2 Study Design

The Phase 2 trial will evaluate the safety and pharmacokinetics of Amigal and ERT when co-administered in 18 male patients with Fabry disease, ages 18-65, who have been receiving ERT for at least one month bef
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... 2012, Fi Asia-China, Hi & Ni China ( ... beverage shows in China, will take place on ... International Expo Centre (SNIEC), organized by UBM Sinoexpo. ... http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg ) As ...
...  For the first time in state of New York, PediaVision ... screener for approximately 125 of the children at Boys & ... Bronx, New York, on Thursday, March 22 beginning at 3 ... vision issues from the Spot screening are provided with the ...
Cached Medicine Technology:Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai 2PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 2PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 3PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 4
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... NEW YORK (July 8, 2014) Researchers from ... College of Medicine of Yeshiva University will present ... being held July 12 July 17 in Copenhagen, ... triggers that could prompt transition from cognitive normality to ... of the Einstein Aging Study , established in ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... , , RADNOR, Pa., ... selected as the NIMH Outreach Partner for the state of ... in each state, Puerto Rico and the District of Columbia. ... over 80 National Partners, including professional, consumer, advocacy, and service-related ...
... ... keynote the upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at ... (Vocus) ... keynote the upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at ...
... , , BOSTON, July 27 ... today with community members and elected officials to celebrate the groundbreaking ... Massachusetts -- the $115 million Kroc Corps Community Center on the ... Chairman of the Kroc Campaign and a longtime supporter of the ...
... divorce and widowhood to poorer health , MONDAY, July 27 (HealthDay ... your health, but it has been less clear how you will ... Now, a new study shows that scenario spells trouble, even if ... who ceased being married at some point in their lives were ...
... N.Y., July 27, 2009By a wide margin, health care ... public and private health plans, and strongly support other ... payment reform and a national insurance health exchange with ... leaders feel it is urgent to enact comprehensive health ...
... , , WALTHAM, Mass., ... ADGE), a leading On-Site Utility offering clean electricity, heat, hot ... facilities, is pleased to announce that it has entered into ... of $3,492,650, which increases the equity of the Company,s common ...
Cached Medicine News:Health News:Feeling Blue Suicide Prevention Council Partners With the National Institute of Mental Health 2Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2Health News:Mayor Menino Joins The Salvation Army to Celebrate the Groundbreaking of the Kroc Community Center 2Health News:Mayor Menino Joins The Salvation Army to Celebrate the Groundbreaking of the Kroc Community Center 3Health News:Marriage Ends, Health Declines 2Health News:Marriage Ends, Health Declines 3Health News:Health care leaders say need for reform is urgent 2Health News:American DG Energy Announces $3.5 Million Private Placement 2
Straight shafts with fine pierse type tips. Flat open serrated handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Medicine Products: